{"filing":{"accession_number":"0001193125-26-391328","cik":"0001839970","ticker":null,"company_name":"BlossomHill Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"d168153d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1839970/000119312526391328/d168153d8k.htm"},"events":[{"id":33467,"run_id":30772,"accession_number":"0001193125-26-391328","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"BlossomHill disclosed updated Phase 1/2 clinical trial data for its lead candidate BH-30643, including a 45% objective response rate and 88% disease control rate in EGFR C797S-positive NSCLC patients, presented at IASLC 2026. This represents a material operational/clinical milestone for a clinical-stage biopharmaceutical company, demonstrating progress toward regulatory advancement (the drug has received FDA Fast Track designation and the company plans to initiate a Phase 2 study in Q1 2027). While not a traditional earnings release or M\u0026A event, the positive clinical efficacy and safety data constitute a material business development milestone that would affect a reasonable investor's assessment of the company's pipeline and prospects.","company_name":"BlossomHill Therapeutics, Inc.","ticker":null,"filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36920,"accession_number":"0001193125-26-391328","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"BlossomHill disclosed updated Phase 1/2 clinical trial data for its lead candidate BH-30643, including a 45% objective response rate and 88% disease control rate in EGFR C797S-positive NSCLC patients, presented at IASLC 2026. This represents a material operational/clinical milestone for a clinical-stage biopharmaceutical company, demonstrating progress toward regulatory advancement (the drug has received FDA Fast Track designation and the company plans to initiate a Phase 2 study in Q1 2027). While not a traditional earnings release or M\u0026A event, the positive clinical efficacy and safety data constitute a material business development milestone that would affect a reasonable investor's assessment of the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T11:31:45.907302+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36920,"accession_number":"0001193125-26-391328","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"BlossomHill disclosed updated Phase 1/2 clinical trial data for its lead candidate BH-30643, including a 45% objective response rate and 88% disease control rate in EGFR C797S-positive NSCLC patients, presented at IASLC 2026. This represents a material operational/clinical milestone for a clinical-stage biopharmaceutical company, demonstrating progress toward regulatory advancement (the drug has received FDA Fast Track designation and the company plans to initiate a Phase 2 study in Q1 2027). While not a traditional earnings release or M\u0026A event, the positive clinical efficacy and safety data constitute a material business development milestone that would affect a reasonable investor's assessment of the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T11:31:45.907302+00:00","company_name":"BlossomHill Therapeutics, Inc.","ticker":null,"filing_date":"2026-09-15"}]}